These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27725568)

  • 1. [Vemurafenib (ZELBORAF
    Shimada T; Yamaguchi K; Aoki T; Kajihara A; Mizui T
    Nihon Yakurigaku Zasshi; 2016; 148(4):197-204. PubMed ID: 27725568
    [No Abstract]   [Full Text] [Related]  

  • 2. Aflibercept, ipilimumab, and vemurafenib.
    Hussar DA; Au AY
    J Am Pharm Assoc (2003); 2012; 52(2):291-4. PubMed ID: 22370387
    [No Abstract]   [Full Text] [Related]  

  • 3. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
    Martin-Liberal J; Larkin J
    Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.
    Kim G; McKee AE; Ning YM; Hazarika M; Theoret M; Johnson JR; Xu QC; Tang S; Sridhara R; Jiang X; He K; Roscoe D; McGuinn WD; Helms WS; Russell AM; Miksinski SP; Zirkelbach JF; Earp J; Liu Q; Ibrahim A; Justice R; Pazdur R
    Clin Cancer Res; 2014 Oct; 20(19):4994-5000. PubMed ID: 25096067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor.
    Aylwin SJ; Bodi I; Beaney R
    Pituitary; 2016 Oct; 19(5):544-6. PubMed ID: 26115708
    [No Abstract]   [Full Text] [Related]  

  • 6. Vemurafenib in melanoma.
    Shaw HM; Nathan PD
    Expert Rev Anticancer Ther; 2013 May; 13(5):513-22. PubMed ID: 23617343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.
    Peyrade F; Re D; Ginet C; Gastaud L; Allegra M; Ballotti R; Thyss A; Zenz T; Auberger P; Robert G
    Haematologica; 2013 Feb; 98(2):e20-2. PubMed ID: 23300174
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful Treatment of Metastatic Upper Tract Urothelial Carcinoma With Vemurafenib: Case Report.
    Ji G; Qian Y
    Clin Genitourin Cancer; 2017 Aug; 15(4):e719-e721. PubMed ID: 28024948
    [No Abstract]   [Full Text] [Related]  

  • 9. 'Basket studies' will hold intricate data for cancer drug approvals.
    Willyard C
    Nat Med; 2013 Jun; 19(6):655. PubMed ID: 23744135
    [No Abstract]   [Full Text] [Related]  

  • 10. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
    Patrawala S; Puzanov I
    Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation.
    Young K; Minchom A; Larkin J
    Future Oncol; 2012 May; 8(5):499-507. PubMed ID: 22646765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.
    Lee EQ; Ruland S; LeBoeuf NR; Wen PY; Santagata S
    J Clin Oncol; 2016 Apr; 34(10):e87-9. PubMed ID: 25092772
    [No Abstract]   [Full Text] [Related]  

  • 14. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib for the treatment of melanoma.
    Jordan EJ; Kelly CM
    Expert Opin Pharmacother; 2012 Dec; 13(17):2533-43. PubMed ID: 23094782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter.
    Bernhardt M; Orouji E; Larribere L; Gebhardt C; Utikal J
    Clin Cancer Res; 2014 May; 20(9):2498-9. PubMed ID: 24789037
    [No Abstract]   [Full Text] [Related]  

  • 17. Vemurafenib. Value unclear in metastatic melanoma.
    Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis.
    Maurer H; Haas P; Wengenmayer T; Lübbert M; Duyster J; Zeiser R
    Ann Hematol; 2014 Aug; 93(8):1439-40. PubMed ID: 24337488
    [No Abstract]   [Full Text] [Related]  

  • 19. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib.
    Follows GA; Sims H; Bloxham DM; Zenz T; Hopper MA; Liu H; Bench A; Wright P; Van't Veer MB; Scott MA
    Br J Haematol; 2013 Apr; 161(1):150-3. PubMed ID: 23278307
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecularly targeted therapies for melanoma.
    Liu LS; Colegio OR
    Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.